- Home
- PINE vs CLLS Comparison
PINE vs CLLS Comparison
Compare PINE & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PINE
- CLLS
- Stock Information
- Founded
- PINE 2019
- CLLS 1999
- Country
- PINE United States
- CLLS France
- Employees
- PINE N/A
- CLLS N/A
- Industry
- PINE Real Estate Investment Trusts
- CLLS Biotechnology: Pharmaceutical Preparations
- Sector
- PINE Real Estate
- CLLS Health Care
- Exchange
- PINE Nasdaq
- CLLS Nasdaq
- Market Cap
- PINE 239.5M
- CLLS 240.2M
- IPO Year
- PINE 2019
- CLLS 2007
- Fundamental
- Price
- PINE $17.64
- CLLS $1.87
- Analyst Decision
- PINE Strong Buy
- CLLS Buy
- Analyst Count
- PINE 9
- CLLS 3
- Target Price
- PINE $19.39
- CLLS $7.00
- AVG Volume (30 Days)
- PINE 78.0K
- CLLS 93.0K
- Earning Date
- PINE 10-17-2024
- CLLS 11-04-2024
- Dividend Yield
- PINE 6.35%
- CLLS N/A
- EPS Growth
- PINE N/A
- CLLS N/A
- EPS
- PINE 0.23
- CLLS N/A
- Revenue
- PINE $50,017,000.00
- CLLS $36,042,000.00
- Revenue This Year
- PINE N/A
- CLLS $271.02
- Revenue Next Year
- PINE $6.04
- CLLS $33.48
- P/E Ratio
- PINE $77.07
- CLLS N/A
- Revenue Growth
- PINE 9.55
- CLLS 46.96
- 52 Week Low
- PINE $14.33
- CLLS $1.70
- 52 Week High
- PINE $19.42
- CLLS $3.77
- Technical
- Relative Strength Index (RSI)
- PINE 45.16
- CLLS 47.58
- Support Level
- PINE $17.59
- CLLS $1.70
- Resistance Level
- PINE $18.10
- CLLS $2.00
- Average True Range (ATR)
- PINE 0.38
- CLLS 0.11
- MACD
- PINE -0.02
- CLLS 0.02
- Stochastic Oscillator
- PINE 16.22
- CLLS 56.67
About PINE Alpine Income Property Trust Inc.
Alpine Income Property Trust Inc is a real estate company. It owns and operates a portfolio of single-tenant commercial properties. The company's portfolio is comprised of single-tenant retail and office properties located in or in close proximity to MSAs, growth markets and other markets in the United States. Their portfolio consists of One thirty eight net leased properties located in Hundred and four markets in thirty five states. The majority of the firm's revenue includes rental revenue derived from the ownership and leasing of property.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC, product candidates in other therapeutic indications.